Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease

NCT02738905 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped insufficient support

Conditions

End Stage Renal Disease

Interventions

DRUG: Rifaximin

Sponsor

Jason Stubbs, MD

Collaborators

[object Object]